This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioDelivery Sciences Provides Business Review And Update In Conjunction With Filing Of Third Quarter 2013 Financials

RALEIGH, N.C., Nov. 12, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2013 and 2014.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

As reported on October 9, 2013, the New Drug Application (NDA) for BDSI's BUNAVAIL (buprenorphine and naloxone buccal film) for the maintenance treatment of opioid dependence has been accepted for filing by the U.S. Food and Drug Administration (FDA), and the agency has assigned a Prescription Drug User Fee Act (PDUFA) date of June 7, 2014.  BDSI believes BUNAVAIL may offer meaningful advantages over existing opioid dependence treatments and could provide an alternative to the over 2 million people estimated in the U.S. to be opioid dependent.  This would create the potential for BUNAVAIL to compete in the estimated $1.5 billion opioid dependence market.    

BDSI and Endo Health Solutions, Inc. also provided a recent update on the BEMA Buprenorphine Phase 3 clinical development program for the treatment of chronic pain.   Interim analyses were conducted as part of the Phase 3 protocol to allow for adjustments to the sample size in order to maintain appropriate study power to detect statistically significant differences between BEMA Buprenorphine and placebo.  The analyses determined that no sample size adjustment was necessary for the opioid naive study.  However, additional patients will be added to the ongoing opioid experienced trial.  Results from the opioid naive trial are expected in early 2014 and data from the opioid experienced trial will be available in mid-2014. 

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,842.25 -85.95 -0.48%
S&P 500 2,075.82 -13.64 -0.65%
NASDAQ 4,908.6860 -30.6410 -0.62%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs